PCR与ELISA检测乙肝病毒的对比及临床意义

The Comparison and Clinical Significance of HBV between PCR and ELISA

目的探讨荧光PCR法检测HBV-DNA定量ELISA定性检测乙肝病毒标志物临床价值比较。方法取受试者空腹血清标本同时以荧光定量PCR法检测HBV-DNA和酶联免疫法检测乙肝病毒两对半。结果 HBV-DNA定量在9.99×108IU/mL^1.00×106IU/mL之间的404例,大三阳比例为85.89%;HBV-DNA定量在9.99×105IU/mL^1.00×103IU/mL之间的416例,小三阳比例为59.38%;HBV-DNA定量在1.00×103IU/ml^1.00×102IU/mL的140例中,HBsAg、HBcAb阳性患者比例为71.43%;HBV-DNA定量<1.00×102IU/mL的992例中,HBsAg、HBeAg阴性模式比例为95.67%。结论荧光定量PCR法检测HBV-DNA和ELISA定性检测HBV表面标记物呈正相关,即HBV-DNA拷贝数多的以大三阳居多,HBV-DNA拷贝数少的以无传染性病毒携带者和阴性者居多。荧光定量PCR可以直接反映体内乙肝病毒感染状态及病毒载量情况,较ELISA更利于判断疾病的严重程度和传染性,更有利于指导临床药物选择和疗效观察。

Objective Analysis of 1952 cases with fluorescent PCR method to detect HBV - DNA quantitative results and ELISA qualitative detection of HBV markers in serum specimens ,and discusses the difference of the two methods and clinical value. Methods Fasting serum specimens of subjects were used with fluorescent quantitative PCR method to detect HBV - DNA and enzyme-linked immunoassay （ELISA） to detect hepatitis b virus （HBV） two half-and-half at the same time. Results HBV-DNA quantitative in 9.99 × 10^8 IU/ml - 1.00 × 1^06 IU/ml 404 cases, the ratio of the patients （HBsAg（＋） HBeAg（＋） HBcAb（＋））was 85.89%; HBV - DNA quantitative in 9.99× 10^5 IU/ml - 1.00 × 10^3 IU/ml 416 cases, the ratio of the patients（HBsAg（＋） HBeAb（＋） HBcAb（＋））was 59.38%; HBV - DNA quantitative in 1.00 × 10^3 IU/ml - 1.00 × 10^5 IU/ml 140 cases, patients with HBsAg, HBcAb positive percentage is 71.43%; HBV- DNA quantitative 〈 1.00 × 105 IU/ml 992 cases, 95.67% HBsAg, HBeAg negative mode. Conclusions The fluorescence quantitative PCR method to detect HBV - DNA and ELISA qualitative detection of HBV surface markers were positively correlated, Most of the HBV - DNA copy number in the majority were HBsAg（＋） HBeAg（＋） HBcAb（＋）,Most of the HBV - DNA copy number less were no infectious virus carder and the negative person. Fluorescence quantitative PCR can directly reflect the state of hepatitis b virus （HBV） infection and viral load, PCR is more conducive to judge the severity and infectious diseases, more conducive to guide clinical drug selection and curative effect observation than ELISA.